Animal models of anxiety and anxiolytic drug action

Dallas Treit, Elif Engin, Kristopher Scott McEown

Research output: Chapter in Book/Report/Conference proceedingChapter

36 Citations (Scopus)

Abstract

Animal models of anxiety attempt to represent some aspect of the etiology, symptomatology, or treatment of human anxiety disorders, in order to facilitate their scientific study. Within this context, animal models of anxiolytic drug action can be viewed as treatment models relevant to the pharmacological control of human anxiety. A major purpose of these models is to identify novel anxiolytic compounds and to study the mechanisms whereby these compounds produce their anxiolytic effects. After a critical analysis of "face," "construct," and "predictive" validity, the biological context in which animal models of anxiety are to be evaluated is specified. We then review the models in terms of their general pharmacological profiles, with particular attention to their sensitivity to 5-HT1A agonists and antidepressant compounds. Although there are important exceptions, most of these models are sensitive to one or perhaps two classes of anxiolytic compounds, limiting their pharmacological generality somewhat, but allowing in depth analysis of individual mechanisms of anxiolytic drug action (e.g., GABAA agonism). We end with a discussion of possible sources of variability between models in response to 5-HT1A agonists and antidepressant drugs.

Original languageEnglish
Title of host publicationBehavioral Neurobiology of Anxiety and Its Treatment
PublisherSpringer-Verlag
Pages121-160
Number of pages40
ISBN (Print)9783642029110
DOIs
Publication statusPublished - 2010 Jan 1
Externally publishedYes

Publication series

NameCurrent Topics in Behavioral Neurosciences
Volume2
ISSN (Print)1866-3370
ISSN (Electronic)1866-3389

Fingerprint

Anti-Anxiety Agents
Anxiety
Animal Models
Serotonin 5-HT1 Receptor Agonists
Pharmaceutical Preparations
Pharmacology
Antidepressive Agents
Anxiety Disorders

Keywords

  • Animal models
  • Antidepressant
  • Anxiety
  • Anxiolytic
  • Biological validity
  • Construct validity
  • Drug receptors
  • Face validity

ASJC Scopus subject areas

  • Medicine(all)
  • Behavioral Neuroscience

Cite this

Treit, D., Engin, E., & McEown, K. S. (2010). Animal models of anxiety and anxiolytic drug action. In Behavioral Neurobiology of Anxiety and Its Treatment (pp. 121-160). (Current Topics in Behavioral Neurosciences; Vol. 2). Springer-Verlag. https://doi.org/10.1007/7854_2009_17

Animal models of anxiety and anxiolytic drug action. / Treit, Dallas; Engin, Elif; McEown, Kristopher Scott.

Behavioral Neurobiology of Anxiety and Its Treatment. Springer-Verlag, 2010. p. 121-160 (Current Topics in Behavioral Neurosciences; Vol. 2).

Research output: Chapter in Book/Report/Conference proceedingChapter

Treit, D, Engin, E & McEown, KS 2010, Animal models of anxiety and anxiolytic drug action. in Behavioral Neurobiology of Anxiety and Its Treatment. Current Topics in Behavioral Neurosciences, vol. 2, Springer-Verlag, pp. 121-160. https://doi.org/10.1007/7854_2009_17
Treit D, Engin E, McEown KS. Animal models of anxiety and anxiolytic drug action. In Behavioral Neurobiology of Anxiety and Its Treatment. Springer-Verlag. 2010. p. 121-160. (Current Topics in Behavioral Neurosciences). https://doi.org/10.1007/7854_2009_17
Treit, Dallas ; Engin, Elif ; McEown, Kristopher Scott. / Animal models of anxiety and anxiolytic drug action. Behavioral Neurobiology of Anxiety and Its Treatment. Springer-Verlag, 2010. pp. 121-160 (Current Topics in Behavioral Neurosciences).
@inbook{85e7c8258e784da9a6267c40db70e00b,
title = "Animal models of anxiety and anxiolytic drug action",
abstract = "Animal models of anxiety attempt to represent some aspect of the etiology, symptomatology, or treatment of human anxiety disorders, in order to facilitate their scientific study. Within this context, animal models of anxiolytic drug action can be viewed as treatment models relevant to the pharmacological control of human anxiety. A major purpose of these models is to identify novel anxiolytic compounds and to study the mechanisms whereby these compounds produce their anxiolytic effects. After a critical analysis of {"}face,{"} {"}construct,{"} and {"}predictive{"} validity, the biological context in which animal models of anxiety are to be evaluated is specified. We then review the models in terms of their general pharmacological profiles, with particular attention to their sensitivity to 5-HT1A agonists and antidepressant compounds. Although there are important exceptions, most of these models are sensitive to one or perhaps two classes of anxiolytic compounds, limiting their pharmacological generality somewhat, but allowing in depth analysis of individual mechanisms of anxiolytic drug action (e.g., GABAA agonism). We end with a discussion of possible sources of variability between models in response to 5-HT1A agonists and antidepressant drugs.",
keywords = "Animal models, Antidepressant, Anxiety, Anxiolytic, Biological validity, Construct validity, Drug receptors, Face validity",
author = "Dallas Treit and Elif Engin and McEown, {Kristopher Scott}",
year = "2010",
month = "1",
day = "1",
doi = "10.1007/7854_2009_17",
language = "English",
isbn = "9783642029110",
series = "Current Topics in Behavioral Neurosciences",
publisher = "Springer-Verlag",
pages = "121--160",
booktitle = "Behavioral Neurobiology of Anxiety and Its Treatment",

}

TY - CHAP

T1 - Animal models of anxiety and anxiolytic drug action

AU - Treit, Dallas

AU - Engin, Elif

AU - McEown, Kristopher Scott

PY - 2010/1/1

Y1 - 2010/1/1

N2 - Animal models of anxiety attempt to represent some aspect of the etiology, symptomatology, or treatment of human anxiety disorders, in order to facilitate their scientific study. Within this context, animal models of anxiolytic drug action can be viewed as treatment models relevant to the pharmacological control of human anxiety. A major purpose of these models is to identify novel anxiolytic compounds and to study the mechanisms whereby these compounds produce their anxiolytic effects. After a critical analysis of "face," "construct," and "predictive" validity, the biological context in which animal models of anxiety are to be evaluated is specified. We then review the models in terms of their general pharmacological profiles, with particular attention to their sensitivity to 5-HT1A agonists and antidepressant compounds. Although there are important exceptions, most of these models are sensitive to one or perhaps two classes of anxiolytic compounds, limiting their pharmacological generality somewhat, but allowing in depth analysis of individual mechanisms of anxiolytic drug action (e.g., GABAA agonism). We end with a discussion of possible sources of variability between models in response to 5-HT1A agonists and antidepressant drugs.

AB - Animal models of anxiety attempt to represent some aspect of the etiology, symptomatology, or treatment of human anxiety disorders, in order to facilitate their scientific study. Within this context, animal models of anxiolytic drug action can be viewed as treatment models relevant to the pharmacological control of human anxiety. A major purpose of these models is to identify novel anxiolytic compounds and to study the mechanisms whereby these compounds produce their anxiolytic effects. After a critical analysis of "face," "construct," and "predictive" validity, the biological context in which animal models of anxiety are to be evaluated is specified. We then review the models in terms of their general pharmacological profiles, with particular attention to their sensitivity to 5-HT1A agonists and antidepressant compounds. Although there are important exceptions, most of these models are sensitive to one or perhaps two classes of anxiolytic compounds, limiting their pharmacological generality somewhat, but allowing in depth analysis of individual mechanisms of anxiolytic drug action (e.g., GABAA agonism). We end with a discussion of possible sources of variability between models in response to 5-HT1A agonists and antidepressant drugs.

KW - Animal models

KW - Antidepressant

KW - Anxiety

KW - Anxiolytic

KW - Biological validity

KW - Construct validity

KW - Drug receptors

KW - Face validity

UR - http://www.scopus.com/inward/record.url?scp=79952255753&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79952255753&partnerID=8YFLogxK

U2 - 10.1007/7854_2009_17

DO - 10.1007/7854_2009_17

M3 - Chapter

C2 - 21309109

AN - SCOPUS:79952255753

SN - 9783642029110

T3 - Current Topics in Behavioral Neurosciences

SP - 121

EP - 160

BT - Behavioral Neurobiology of Anxiety and Its Treatment

PB - Springer-Verlag

ER -